Berger’s Disease: How IgA Nephropathy Damages Kidneys Over Time

Berger’s disease is IgA nephropathy, a kidney disorder in which immunoglobulin A (IgA) antibody deposits lodge in the glomeruli, the tiny filtering units of the kidney, and trigger inflammation that slowly scars them. It is the most common primary glomerulonephritis worldwide, affecting roughly 2.5 per 100,000 people each year in the United States, with peak onset in the 20s and 30s. Most people notice only blood or protein in the urine. However, about 20 to 30 percent of affected adults reach kidney failure within 20 to 25 years of diagnosis, so Berger's disease is a chronic, progressive condition rather than a benign one.

What Berger's Disease Actually Is

Berger's disease takes its name from Jean Berger, the French pathologist who described the condition with Nicole Hinglais in 1968. Under a microscope, the hallmark is IgA deposited in the mesangium, the connective stalk at the center of each glomerulus. This is a defining feature: no other common kidney disease shows dominant IgA deposits in that location.

The core abnormality is an immune molecule problem, not a problem with the kidney itself. In most cases, people with IgA nephropathy carry a version of IgA1 with an abnormal sugar side chain. Specifically, the hinge region of IgA1 is missing a galactose molecule, a state called galactose-deficient IgA1, or Gd-IgA1. Roughly 80 to 90 percent of biopsies in IgA nephropathy show these deposits.

The kidney damage is the end result of a multi-step cascade. First, the bone marrow produces too much Gd-IgA1. Second, circulating antibodies recognize the abnormal hinge and bind to it, forming immune complexes. Third, those complexes deposit in the mesangium. Fourth, the mesangial cells release inflammatory cytokines and multiply, which promotes scarring of the glomerulus. In plain terms: the immune system produces a slightly malformed antibody, and the kidney becomes the filter that traps it.

The Four-Hit Hypothesis: Why the Immune System Turns on the Kidney

The modern explanation is called the four-hit hypothesis, published by Suzuki and colleagues in 2011. It is the field's leading framework, though it remains a model rather than a proven certainty.

Each step in the cascade contributes, and no single hit alone produces the disease. This explains why IgA nephropathy runs in families and why identical twins show 60 to 80 percent concordance, which points to a substantial genetic component. In population genetics, the most consistently replicated risk locus is the MHC region on chromosome 6, though genome-wide association studies have identified many other loci with smaller effects.

The four-hit model also explains why no single hit is a switch. Blood tests for Gd-IgA1 have decent but imperfect predictive value, which is why they are not used for diagnosis and only biopsy confirms the disease.

How Fast Berger's Disease Progresses: A Timeline

Progression is highly variable. Some patients have stable disease for decades, and others lose most kidney function within 10 to 15 years. The timeline table below reflects typical adult patterns.

The decline rate is the most important clinical marker. A slow decline of 1 to 2 mL/min per year is typical of stable disease. A rapid decline of more than 5 mL/min per year occurs in 10 to 15 percent of patients and predicts early kidney failure. Those patients warrant aggressive treatment.

Variations and Edge Cases: Not All Presentations Behave Alike

Berger's disease has several distinct presentations and subgroups, and the differences matter clinically.

Macroscopic hematuria varies by age. In children, 30 to 50 percent of cases present with visibly bloody urine after a respiratory infection, which is often mistaken for a urinary tract infection. In adults, this presentation is less common; adults more often have microscopic blood found on routine urine testing.

The IgA nephropathy versus Henoch-Schönlein purpura distinction is an important edge case. These are the same disease process, but the systemic form, historically called Henoch-Schönlein purpura and now called IgA vasculitis, adds skin purpura, abdominal pain, and joint pain. The kidney findings are identical on biopsy. The difference lies in whether the IgA deposits also involve blood vessels in the skin and gut. Roughly 30 to 50 percent of patients with IgA vasculitis develop kidney involvement, usually within 4 weeks of the rash.

The ethnic pattern is another variation. IgA nephropathy is up to 3 times more common in East Asians than in people of European descent, and up to 4 to 5 times more common than in people of African descent. This likely reflects a mixture of genetic susceptibility and diagnostic rates, since biopsy practice varies by country.

The female pattern is subtle. Women tend to have lower proteinuria at diagnosis and a slightly slower progression rate, but the long-term risk difference is small and not a reason to relax surveillance.

The Kidney Failure Risk: What the Numbers Actually Show

Berger's disease is more serious than its reputation suggests. A cohort meta-analysis found that about 25 percent of adults with the disease progress to kidney failure within 25 years, and a further 20 to 30 percent require some form of specialist kidney care. This is not a minor condition.

The main laboratory predictors are proteinuria, blood pressure, and the filtration rate at diagnosis. In clinical studies, patients with proteinuria above 1 g/day have a roughly 3 to 5 times higher risk of progression than those below 1 g/day. Patients with a filtration rate already below 60 mL/min/1.73 m² at diagnosis have a higher risk of kidney failure. These thresholds are the ones used in the 2021 KDIGO glomerulonephritis guideline for treatment decisions.

A clinical risk tool called the International IgA Nephropathy Prediction Tool, validated in 2022 and published by the International IgA Nephropathy Network, estimates a 5-year risk of a 50 percent drop in kidney function using age, blood pressure, proteinuria, and biopsy features. The tool gives an estimated 5-year risk that ranges from low (under 5 percent) to high (above 20 percent). This risk stratification is now used in practice to guide treatment intensity.

Proteinuria is the most modifiable target. Each 1 g/day reduction in proteinuria correlates with a substantially lower risk of kidney failure, and many trials treat a proteinuria goal below 0.5 to 1 g/day as a marker of treatment success.

Misconceptions and a Professional Caveat

Several common misconceptions deserve correction.

First, there is a widespread belief that IgA nephropathy is mildly progressive and rarely progresses to advanced disease. That is inaccurate. A 20 to 30 percent kidney failure rate over 20 to 25 years is substantial, which is why so many new therapies are in development.

Second, some people believe a normal creatinine level means the disease is not active. It does not. A normal creatinine can coexist with active inflammation, since up to 50 percent of the filtering capacity can be lost before creatinine rises above the reference range. Urine protein, not creatinine alone, is the better early warning.

Third, there is a belief that children with the condition will outgrow it. Some do, but a follow-up study of childhood cases found that 20 to 30 percent still had persistent disease into adulthood.

One professional caveat: a biopsy showing IgA deposits is necessary for diagnosis, but the amount of IgA seen on immunofluorescence does not predict the trajectory. The extent of mesangial proliferation and of glomerulosclerosis on light microscopy predicts better. Do not ask about the deposit intensity; ask about the biopsy score.

What to Actually Do: Practical Steps for Monitoring and Treatment

For anyone with a confirmed diagnosis, several concrete actions reduce the risk of progression.

Get regular urine protein testing. A spot urine protein-to-creatinine ratio every 3 to 6 months gives a trend, which is more useful than a single value. A ratio that stays below 0.5 g/g suggests stable disease; one above 1 g/g signals active disease.

Control blood pressure to a target below 130/80 mm Hg. The 2021 KDIGO guideline recommends a target systolic pressure below 120 mm Hg when tolerated, based on evidence that tighter control slows progression.

Ask about renin-angiotensin system blockade early. An ACE inhibitor or ARB is first-line for proteinuria reduction, and the evidence shows these drugs reduce proteinuria by 30 to 40 percent.

Watch for these red-flag warning signs and call a clinician promptly:

• A single urine protein reading above 1 g/day that persists for more than 3 months
• A rising creatinine of more than 30 percent in 6 months
• Visible blood in the urine that lasts more than a few days after an infection
• New swelling of the legs or face
• Blood pressure that stays above 140/90 mm Hg despite treatment
• A drop in the estimated filtration rate of more than 5 mL/min per year

Newer treatment options also change the landscape. In 2021, the FDA approved the first targeted therapy for IgA nephropathy, a delayed-release budesonide formulation, based on trial data showing a meaningful reduction in proteinuria. The 2021 KDIGO guideline recommends considering systemic corticosteroids for patients at high risk, though steroids carry substantial side-effect burdens and are not appropriate for everyone. A comparison table of treatment options below summarizes the tradeoffs.

The choice of therapy depends on proteinuria level, blood pressure, and the biopsy findings. No single treatment is right for everyone.

Limitations and What Remains Uncertain

Berger's disease research is moving fast, but important limitations remain. The four-hit hypothesis is a model, not a proven cause, and no therapy targets its earliest steps directly yet. The prediction tool estimates risk well at a population level but is less precise for individual patients. And the long-term data for newer treatments currently extend only a few years, so the 20-year outcomes for patients treated with budesonide or other novel agents are not yet known.

Finally, a diagnosis is a starting point, not a label for the rest of a person's life. Many patients, particularly those diagnosed in childhood with mild features, maintain normal kidney function for decades. But the condition deserves active monitoring: the difference between a stable course and a progressive one is often a matter of catching and treating proteinuria early.

One number to keep in mind: a reduction in proteinuria of 1 g/day is associated with roughly a 50 percent lower risk of kidney failure in observational cohorts. That figure is why proteinuria, not creatinine, is the number most worth tracking.